.jpg)
1 hour ago
3
Article content
- Teva-discovered TEV-’408 targets IL-15, a key driver of vitiligo biology
- TEV-’408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to date
- Nearly 75% of patients reported improvement in facial vitiligo, with half reporting “much’ or “very much” improved
- TEV-’408 is designed for convenient quarterly (Q12W) subcutaneous dosing
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Teva will hold an investor call and live webcast today,
Tuesday, July 7, 2026, at 8:00 a.m. ET to discuss these data.
Article content
Article content
Article content
TEL AVIV, Israel, July 07, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to advance its TEV-’408, an investigational anti-interleukin-15 monoclonal antibody, into a Phase 2b study in vitiligo in the fourth quarter of 2026. The decision follows encouraging results from an ongoing Phase 1b, open-label study in adults with active or stable non-segmental vitiligo (NSV).
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Data from the ongoing, open-label Phase 1b study showed improvements in skin pigmentation in patients with active or stable NSV. TEV-’408 was well-tolerated with no safety signals observed to date. At baseline, 66% of enrolled participants had vitiligo affecting more than 10% of body surface area, representing a population with limited treatment options. At week 24, in evaluable participants:
Article content
- Nearly 75% of patients reported improvement in facial vitiligo, with half reporting “much” or “very much” improved
- 42% achieved F-VASI50 and 21% achieved F-VASI75
- 55% of patients reported improvement in total body vitiligo
- 7% achieved T-VASI50
Article content
Article content
“TEV-’408 exemplifies the type of innovative, Teva-discovered program we are prioritizing as we continue to advance and strengthen our immunology pipeline,” said Richard Francis, President and Chief Executive Officer of Teva. “Grounded in compelling biology and focused on meaningful unmet need, TEV-’408 reflects our progress in our Pivot to Growth strategy and our commitment to pursuing differentiated innovation for patients.”
Article content
Vitiligo is a chronic autoimmune disease that causes loss of skin pigmentation and can have a significant impact on quality of life, self-image, and daily social interactions. Despite recent advances, treatment options remain limited, particularly for patients with more extensive disease, who may require systemic therapy, or those seeking better disease control.
Article content
“Vitiligo can affect far more than the skin. It can shape how people see themselves, how they show up in the world, and the confidence they carry every day,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. “These encouraging data strengthen our confidence in the IL-15 pathway and reflect the depth of Teva’s scientific expertise. We are excited by the potential of this program to offer a meaningful new option for people living with vitiligo.”
English (US)